Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06803342 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
A Phase 2 study of Ebola Sudan Virus Disease, sponsored by Albert B. Sabin Vaccine Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT06803342 is a Phase 2 study of Ebola Sudan Virus Disease that is active but no longer recruiting, run by Albert B. Sabin Vaccine Institute. The registered enrollment target is 200 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT06803342, a Phase 2 study of Ebola Sudan Virus Disease, is active but no longer recruiting, sponsored by Albert B. Sabin Vaccine Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL cAd3-Sudan Vaccine
Study Locations (4)
Arizona
- Synexus Clinical Research US, Inc. - Phoenix
Florida
- Optimal Research; LLC - Melbourne
Illinois
- Synexus Clinical Research US, Inc. - Chicago
Texas
- Synexus Clinical Research US, Inc. - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-06-26 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06803342
The ClinicalTrials.gov registry entry for NCT06803342 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert B. Sabin Vaccine Institute, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ebola Sudan Virus Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06803342 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06803342 about?
NCT06803342 is a clinical study titled "A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults". A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
What is the current status of trial NCT06803342?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-06-26. Estimated completion is 2027-04.
What conditions does trial NCT06803342 study?
This clinical trial studies the following conditions: Ebola Sudan Virus Disease.
What interventions are being tested in trial NCT06803342?
The interventions under investigation include: Placebo (BIOLOGICAL), cAd3-Sudan Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06803342?
This trial is sponsored by Albert B. Sabin Vaccine Institute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06803342 being conducted?
This trial has 4 study locations across Arizona, Florida, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.